Acute promyelocytic leukemia differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
Shyam Patel (talk | contribs) |
Shyam Patel (talk | contribs) |
||
| Line 43: | Line 43: | ||
| | | | ||
* Presence of Auer rods in promyelocytes | * Presence of Auer rods in promyelocytes | ||
* High risk for early death from hemorrhagic complications | * High risk for early death from hemorrhagic complications<ref name="pmid21993679">{{cite journal| author=McClellan JS, Kohrt HE, Coutre S, Gotlib JR, Majeti R, Alizadeh AA et al.| title=Treatment advances have not improved the early death rate in acute promyelocytic leukemia. | journal=Haematologica | year= 2012 | volume= 97 | issue= 1 | pages= 133-6 | pmid=21993679 | doi=10.3324/haematol.2011.046490 | pmc=3248942 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21993679 }} </ref> | ||
|- | |- | ||
|Acute myeloid leukemia | |Acute myeloid leukemia | ||
| Line 62: | Line 62: | ||
* Elevated potassium | * Elevated potassium | ||
* Low calcium | * Low calcium | ||
* Greater than 20% myeloblasts on bone marrow aspirate | * Greater than 20% myeloblasts on bone marrow aspirate<ref name="pmid27895058">{{cite journal| author=Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T et al.| title=Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. | journal=Blood | year= 2017 | volume= 129 | issue= 4 | pages= 424-447 | pmid=27895058 | doi=10.1182/blood-2016-08-733196 | pmc=5291965 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27895058 }} </ref> | ||
| | | | ||
* Pyrexia | * Pyrexia | ||
| Line 100: | Line 100: | ||
* Lymphadenopathy | * Lymphadenopathy | ||
| | | | ||
* HyperCVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone) | * HyperCVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone)<ref name="pmid28665419">{{cite journal| author=Terwilliger T, Abdul-Hay M| title=Acute lymphoblastic leukemia: a comprehensive review and 2017 update. | journal=Blood Cancer J | year= 2017 | volume= 7 | issue= 6 | pages= e577 | pmid=28665419 | doi=10.1038/bcj.2017.53 | pmc=5520400 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28665419 }} </ref> | ||
* R-HyperCVAD (inclusion of rituximab) | * R-HyperCVAD (inclusion of rituximab) | ||
* Peg-asparaginase | * Peg-asparaginase | ||
| Line 110: | Line 110: | ||
* [[Stem cell transplant]] | * [[Stem cell transplant]] | ||
| | | | ||
* Sanctuary sites include the central nervous system (CNS) and testes | * Sanctuary sites include the central nervous system (CNS) and testes<ref name="pmid23523389">{{cite journal| author=Inaba H, Greaves M, Mullighan CG| title=Acute lymphoblastic leukaemia. | journal=Lancet | year= 2013 | volume= 381 | issue= 9881 | pages= 1943-55 | pmid=23523389 | doi=10.1016/S0140-6736(12)62187-4 | pmc=3816716 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23523389 }} </ref> | ||
|- | |- | ||
|Chronic myeloid leukemia | |Chronic myeloid leukemia | ||
| Line 131: | Line 131: | ||
* [[Bosutinib]] | * [[Bosutinib]] | ||
* [[Ponatinib]] | * [[Ponatinib]] | ||
* [[Omacetaxine]] | * [[Omacetaxine]]<ref name="pmid24516334">{{cite journal| author=Chen Y, Li S| title=Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia. | journal=Onco Targets Ther | year= 2014 | volume= 7 | issue= | pages= 177-86 | pmid=24516334 | doi=10.2147/OTT.S41786 | pmc=3916637 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24516334 }} </ref> | ||
| | | | ||
* High response rate to tyrosine kinase inhibitors | * High response rate to tyrosine kinase inhibitors | ||
| Line 159: | Line 159: | ||
* Cyclophosphamide | * Cyclophosphamide | ||
* Rituximab | * Rituximab | ||
* Obinutuzumab | * Obinutuzumab<ref name="pmid28182141">{{cite journal| author=Al-Sawaf O, Fischer K, Engelke A, Pflug N, Hallek M, Goede V| title=Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy. | journal=Drug Des Devel Ther | year= 2017 | volume= 11 | issue= | pages= 295-304 | pmid=28182141 | doi=10.2147/DDDT.S104869 | pmc=5279834 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28182141 }} </ref> | ||
* Ofatumumab | * Ofatumumab | ||
* Ibrutinib | * Ibrutinib | ||
Revision as of 22:51, 29 May 2018
|
Acute promyelocytic leukemia Microchapters |
|
Differentiating Acute promyelocytic leukemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Acute promyelocytic leukemia differential diagnosis On the Web |
|
American Roentgen Ray Society Images of Acute promyelocytic leukemia differential diagnosis |
|
Acute promyelocytic leukemia differential diagnosis in the news |
|
Blogs on Acute promyelocytic leukemia differential diagnosis |
|
Directions to Hospitals Treating Acute promyelocytic leukemia |
|
Risk calculators and risk factors for Acute promyelocytic leukemia differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]
Differentiating Acute promyelocytic meukemia from other Diseases
Acute promyelocytic leukemia can be distinguished from other types of AML based on a variety of features.
| Characteristic | Causes | Laboratory abnormalities | Physical examination | Therapy | Other associations |
|---|---|---|---|---|---|
| Acute promyelocytic leukemia |
|
|
|
|
|
| Acute myeloid leukemia |
|
|
|
|
|
| Acute lymphoblastic leukemia |
|
|
|
|
|
| Chronic myeloid leukemia |
|
|
|
| |
| Chronic lymphocytic leukemia[6] |
|
|
|
|
|
References
- ↑ McClellan JS, Kohrt HE, Coutre S, Gotlib JR, Majeti R, Alizadeh AA; et al. (2012). "Treatment advances have not improved the early death rate in acute promyelocytic leukemia". Haematologica. 97 (1): 133–6. doi:10.3324/haematol.2011.046490. PMC 3248942. PMID 21993679.
- ↑ Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T; et al. (2017). "Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel". Blood. 129 (4): 424–447. doi:10.1182/blood-2016-08-733196. PMC 5291965. PMID 27895058.
- ↑ Terwilliger T, Abdul-Hay M (2017). "Acute lymphoblastic leukemia: a comprehensive review and 2017 update". Blood Cancer J. 7 (6): e577. doi:10.1038/bcj.2017.53. PMC 5520400. PMID 28665419.
- ↑ Inaba H, Greaves M, Mullighan CG (2013). "Acute lymphoblastic leukaemia". Lancet. 381 (9881): 1943–55. doi:10.1016/S0140-6736(12)62187-4. PMC 3816716. PMID 23523389.
- ↑ Chen Y, Li S (2014). "Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia". Onco Targets Ther. 7: 177–86. doi:10.2147/OTT.S41786. PMC 3916637. PMID 24516334.
- ↑ Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG; et al. (2017). "Chronic lymphocytic leukaemia". Nat Rev Dis Primers. 3: 16096. doi:10.1038/nrdp.2016.96. PMC 5336551. PMID 28102226.
- ↑ Al-Sawaf O, Fischer K, Engelke A, Pflug N, Hallek M, Goede V (2017). "Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy". Drug Des Devel Ther. 11: 295–304. doi:10.2147/DDDT.S104869. PMC 5279834. PMID 28182141.